Zeng et al
Topical application of imiquimod (IMQ), a TLR7/8 ligand and potent immune activator, can induce and exacerbate psoriasis, a chronic inflammatory skin disorder
In mice, the topical application of imiquimod (IMQ), a ligand of Toll-like receptors (TLR) 7 and 8, has been reported to induce psoriasis-like dermatitis
Various types of cytokine are involved in the modulation of inflammatory responses in inflammatory skin diseases like psoriasis
Our study reveals the immune environment characteristics of the commonly used IMQ induced psoriasis-like models and provides a systematic insight into the
Topical medicines are the preferred treatment for mild to moderate psoriasis, but the effect of excipients used in semi-solid preparations on psoriasis-like skin inflammation is not
Topical medicines are the preferred treatment for mild to moderate psoriasis, but the effect of excipients used in semi-solid preparations on psoriasis-like skin
1
Psoriasis is a chronic and immune-mediated disease associated with environmental and genetic factors that affect 2–3% of the worldwide population 1,2
Psoriasis is a chronic immune-mediated inflammatory disease that affects the skin
IMQ was used induce psoriasis-like inflammation to establish the mouse model of
Therefore, in this study, we developed a mouse model of psoriatic skin lesions Psoriasis is an immune-mediated systemic disease that may be treated with probiotics
and applied imiquimod (IMQ), a ligand of TLR7/8 and effective potent immune activator, on the dorsal skin to induce A mouse model of imiquimod-induced psoriasis skin inflammation was carried out to determine its efficacy by histological analysis, RNA extraction, and RT-qPCR assays
To define the crucial cell type responding to IL Aim: To investigate the effect of cerium oxide nanoparticles (nanoceria) on psoriasis
Using an imiquimod (IMQ)-induced murine model of psoriasiform dermatitis, we also investigated the level of CD49a + Trm cells in acute, chronic and resolved
Acarbose was found to decrease inflammatory parameters in diabetic patients in addition to its anti-diabetic effects
The topical
A patient with pre-existing psoriasis that had been stable for 14 years was treated with imiquimod 5% cream daily for 6 weeks to three superficial basal cell carcinomas